KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Met

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.

Related Keywords

, Exploring Hepatotoxicity , Treatment Outcomes , Adverse Events , Lung Cancer , Nsclc , Non Small Cell Lung Cancer , Mnsclc , Metastatic Lung Cancer , Metastatic Nsclc , Metastatic Non Small Cell Lung Cancer ,